SEARCH:   Advanced

Blood, 1 November 2007, Vol. 110, No. 9, pp. 3310-3315. Prepublished online as a Blood First Edition Paper on July 13, 2007; DOI 10.1182/blood-2007-05-086934. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-05-086934v1 110/9/3310    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Niens, M. Articles by van den Berg, A. Search for Related Content PubMed PubMed Citation Articles by Niens, M. Articles by van den Berg, A. Related Collections Immunobiology Neoplasia Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma Marijke Niens1, Ruth F. Jarrett2, Bouke Hepkema3, Ilja M. Nolte4, Arjan Diepstra5, Mathieu Platteel1, Niels Kouprie3, Craig P. Delury2, Alice Gallagher2, Lydia Visser5, Sibrand Poppema5, Gerard J. te Meerman1, and Anke van den Berg5 1 Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 2 Leukemia Research Fund (LRF), Virus Centre, Institute of Comparative Medicine, University of Glasgow, Glasgow, United Kingdom; 3 Department of Transplantation Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 4 Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 5 Department of Pathology and Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Previous studies showed that the HLA class I region is associated with Epstein-Barr virus (EBV)–positive Hodgkin lymphoma (HL) and that HLA-A is the most likely candidate gene in this region. This suggests that antigenic presentation of EBV-derived peptides in the context of HLA-A is involved in the pathogenesis of EBV+ HL by precluding efficient immune responses. We genotyped exons 2 and 3, encoding the peptide-binding groove of HLA-A, for 32 single nucleotide polymorphisms in 70 patients with EBV+ HL, 31 patients with EBV– HL, and 59 control participants. HLA-A*01 was significantly overrepresented and HLA-A*02 was significantly underrepresented in patients with EBV+ HL versus controls and patients with EBV– HL. In addition, HLA-A*02 status was determined by immunohistochemistry or HLA-A*02–specific polymerase chain reaction (PCR) on 152 patients with EBV+ HL and 322 patients with EBV– HL. The percentage of HLA-A*02+ patients in the EBV+ HL group (35.5%) was significantly lower than in 6107 general control participants (53.0%) and the EBV– HL group (50.9%). Our results indicate that individuals carrying the HLA-A*02 allele have a reduced risk of developing EBV+ HL, while individuals carrying the HLA-A*01 allele have an increased risk. It is known that HLA-A*02 can present EBV-derived peptides and can evoke an effective immune response, which may explain the protective phenotype. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: A mechanism for the HLA-A*01–associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis Rebekah M. Brennan and Scott R. Burrows Blood 2008 112: 2589-2590. [Full Text] [PDF] This article has been cited by other articles: M. L. Gulley and W. Tang Laboratory Assays for Epstein-Barr Virus-Related Disease J. Mol. Diagn., July 1, 2008; 10(4): 279 - 292. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020